Structure Therapeutics recently reported positive topline Phase 2b and related ACCESS program data for its oral GLP-1 agonist aleniglipron in adults with obesity or overweight, showing clinically ...
AppLovin (APP) stock is rated Strong Buy with 32% upside. Learn about its AI-driven ad tech, growth, and premium valuation.
Zacks Investment Research on MSN
GPCR stock soars 102% on strong phase II obesity data for Aleniglipron
Shares of Structure Therapeutics GPCR skyrocketed 102.5% after the company reported positive top-line data from the ACCESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results